Ambiguous data from two Phase III trials treating agitation in patients with dementia of the Alzheimer's type using Rexulti (brexpiprazole) were deemed insufficient by FDA, prompting plans by H. Lundbeck A/S and its Japanese partner to initiate a third study around the second quarter of this year, according to the brain-focused Danish biotech.
"We will initiate a third study together with Otsuka Pharmaceutical Co. Ltd. and expect to do that sometime during...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
